Back to top
more

Akero Therapeutics (AKRO)

(Delayed Data from NSDQ)

$26.41 USD

26.41
446,533

+0.06 (0.23%)

Updated Sep 6, 2024 04:00 PM ET

After-Market: $26.41 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for AKRO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Akero Therapeutics, Inc. [AKRO]

Reports for Purchase

Showing records 21 - 40 ( 108 total )

Company: Akero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 21

11/07/2022

Company Report

Pages: 10

3Q Recap; EFX Met Both Key NASH Endpoints in Phase 2b HARMONY Study; Cohort D Readout in 1H23; Raise PT to $64

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Akero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 22

08/08/2022

Company Report

Pages: 8

2Q Recap: We Remain Highly Confident in a Positive Top-line Data Readout for Phase 2b HARMONY Next Month; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Akero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 23

07/14/2022

Daily Note

Pages: 3

Healthcare Coverage Update - Dropping Coverage

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Akero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 24

05/09/2022

Company Report

Pages: 8

1Q Recap; Phase 2b HARMONY Top-Line Data Readout in 3Q22 Represents Major Milestone for Akero; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Akero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 25

02/28/2022

Company Report

Pages: 8

4Q Recap; HARMONY Top-Line Results Remain on Target for 3Q22; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Akero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 26

02/09/2022

Daily Note

Pages: 3

HARMONY Study Completes Enrollment; Top-line Data on Target in 3Q22; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Akero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 27

11/15/2021

Company Report

Pages: 9

3Q Review; AASLD Data Show Impressive Evidence of Histologic Improvements Broadly at Just 16 Weeks

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Akero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 28

10/20/2021

Daily Note

Pages: 3

FDA Grants Fast Track Designation for EFX in the Treatment of NASH; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Akero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 29

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for AKRO

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Akero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 30

08/16/2021

Company Report

Pages: 9

2Q Recap: Two Phase 2b Trials Enrolling Patients With Both Fibrotic and Cirrhotic NASH; Affirm Buy, Modulate PT to $64

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Akero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 31

05/14/2021

Company Report

Pages: 8

1Q21 Recap: HARMONY and SYMMETRY for Treating All Stages of NASH; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Akero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 32

03/23/2021

Company Report

Pages: 6

Raise Price Target to $68 on Clear Win for Early Data in Cirrhotic NASH; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Akero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 33

03/17/2021

Company Report

Pages: 8

4Q20 Recap: As Enrollment in HARMONY Continues, Cohort C Data Next Month a Key Catalyst

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Akero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 34

02/24/2021

Daily Note

Pages: 3

Screening of Patients Underway for Phase 2b HARMONY Study of EFX; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Akero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 35

11/13/2020

Company Report

Pages: 8

3Q20 Recap: Full Results of the Phase 2a BALANCED Study of EFX at AASLD; Raise PT to $64

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Akero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 36

10/19/2020

Daily Note

Pages: 3

EFX First Drug to Receive PRIME Designation for the Treatment of NASH

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Akero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 37

10/02/2020

Industry Report

Pages: 58

Final Program for Our Fourth Annual Virtual NASH Investor Conference

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 100.00

Research Provided by a Third Party

Company: Akero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 38

09/30/2020

Daily Note

Pages: 3

BALANCED Trial Cohort C Fully Enrolled; First Cirrhotic NASH Data in 1H21; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Akero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 39

09/29/2020

Industry Report

Pages: 59

Program for Our Fourth Annual Virtual NASH Investor Conference, October 5

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 100.00

Research Provided by a Third Party

Company: Akero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 40

09/25/2020

Daily Note

Pages: 3

Plans for Adaptive Phase 2b/3 of EFX to Proceed with Written Guidance from the FDA; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party
// eof